Edition:
India

Aldeyra Therapeutics expands retinal disease pipeline with acquisition of Helio Vision


Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS EXPANDS RETINAL DISEASE PIPELINE WITH ACQUISITION OF HELIO VISION.ALDEYRA THERAPEUTICS INC - INITIAL CLINICAL TRIAL RESULTS EXPECTED IN 2020.ALDEYRA THERAPEUTICS - ACQUIRED HELIO VISION FOR AN UPFRONT PAYMENT OF APPROXIMATELY $10 MILLION IN COMMON STOCK, SUBJECT TO A SIX-MONTH LOCK-UP PERIOD,.ALDEYRA THERAPEUTICS INC - ACQUISITION OF HELIO VISION AND NEAR-TERM DEVELOPMENT OF ADX-2191 HAS NO IMPACT ON CO'S PREVIOUS FINANCIAL GUIDANCE.ALDEYRA THERAPEUTICS INC - UNDER DEAL, UPFRONT PAYMENT ALSO HAS AN ADDITIONAL $2.5 MILLION PAYMENT IN COMMON STOCK TWO YEARS FROM DATE OF CLOSING.ALDEYRA THERAPEUTICS INC - ADAPTIVE PHASE 3 CLINICAL PROGRAM FOR ADX-2191 IN PVR IS EXPECTED TO INITIATE IN 2019, WITH RESULTS EXPECTED IN 2020.ALDEYRA THERAPEUTICS - UNDER TERMS, ELIOTT & OTHER CO-FOUNDERS OF HELIO VISION WILL CONTINUE TO WORK WITH ALDEYRA ON ADX-2191 AS CONSULTANTS.